English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The European Society of Cardiology (ESC) Working Group (WG) on Cardiovascular Pharmacotherapy works with all aspects of cardiovascular pharmacotherapy: From basic pharmacology over clinical trials to clinical pharmacotherapy. Over the last years, the WG has focused on: Polypharmacy, for example the heart failure patient treated with various drugs for the heart as well as for comorbidities. On sudden cardiac death, for example the treatment of arrhythmia as well as the prevention of pharmacologically induced arrhythmia. Moreover, on clinical trials science, for example on optimum planning and conduction of clinical trials, on optimum evaluation of results as well as on development of new types of trials.The WG presently consists of ∼300 members. To apply for membership go to www.escardio.org/pharmacology. Membership is free to members of national cardiology societies within ESC. Membership is granted based on shown interest in cardiovascular …

European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy. The chairman's report at the general assembly 2014